Arecor Therapeutics PLC Ordinary Shares AREC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX72.50
- Day Range
- GBX71.00–75.00
- 52-Week Range
- GBX55.27–95.00
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 45.11M
- Market Cap
- GBX3.27B
- Volume/Avg
- 1,009 / 27,139
Key Statistics
- Price/Earnings (Normalized)
- 53.40
- Price/Sales
- 147.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.arecor.com
Valuation
|
Metric
|
AREC
|
|---|---|
Price/Earnings (Normalized) | 53.40 |
Price/Book Value | 23.12 |
Price/Sales | 147.39 |
Price/Cash Flow | — |
Price/Earnings
AREC
Financial Strength
|
Metric
|
AREC
|
|---|---|
Quick Ratio | 4.29 |
Current Ratio | 4.69 |
Interest Coverage | −17.13 |
Quick Ratio
AREC
Profitability
|
Metric
|
AREC
|
|---|---|
Return on Assets (Normalized) | −56.69% |
Return on Equity (Normalized) | −160.51% |
Return on Invested Capital (Normalized) | −78.56% |
Return on Assets
AREC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|qj%T>Q | LOCK|LSklW | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&yG#D?^ | LOCK|X$mp% | $76B | |||
| Moderna Inc
MRNA
| LOCK|K&kTmm | LOCK|wT | $75B | |||
| argenx SE ADR
ARGX
| LOCK|^fyZ?&F | LOCK|CL$ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^nC!t? | LOCK|CF | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>N?##x | LOCK|RDXJl | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$&XbtFt^ | LOCK|w$?x^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?>rhJ!? | LOCK|qZf | $24B | |||
| Incyte Corp
INCY
| LOCK|k^l%H!? | LOCK|K#< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!&xTPJq | LOCK|X!R | $15B |
United States